Peptides were analysed on a LC-MS/MS workflow comprising a Dionex Ultimate 3000 nLC system coupled to a Q-Exactive mass spectrometer (Thermo Scientific) [5, 6] . Briefly, chromatographic separation was achieved using a 50cm nEASY spray column (Thermo Scientific, (PepMAP C18, 75 µm x 500mm, 2 µm particle size) and a linear acetonitrile gradient from 2-35% in 5% DMSO and 0.1% formic acid. Precursor peptides were detected with a resolution of 70000 at 200m/z followed by the selection of up to 15 precursor ions. Raw data was imported into Progenesis QI (Waters, V4.1.4832.42146) for label-free quantitation and alignment, and peptides were identified with PEAKS (Bioinformatics Solutions, V7). The abundance of citrullinated peptides was normalised to the abundance of their non-citrullinated counterparts, which value was further normalised to the citrullinated peptide abundance detected in a non-citrullinated FBG control sample.
Differential Scanning Fluorimetry and Circular Dichroism
Five μM FBG was mixed with 5x SYPRO® orange protein gel stain (Life Technologies) in citrullination buffer and melting curves from 38 ˚C up to 99 ˚C recorded on the Applied Biosystems ViiA 7 RealTime PCR System (excitation 550 nm, emission, 586 nm). The melting temperature (Tm) of each sample was defined as the maximum of the first derivate of the fluorescence. Circular dichroism spectra of FBG samples (200 μg/ml) were recorded using a Jasco J-815 CD Spectrometer, between 210 and 270 nm.
Peptides
Peptides from tenascin-C (accession number P24821) and fibrinogen  (P02675) and  (P02679) chains (Table S1 and S2) were synthesized at a purity > 90-95%, with C-and N-terminal cysteines (Pepceuticals) and solubilized in water at 10 mg/ml. CEP-1, cVIM and cFIBβ peptides used for crossreactivity assays are described elsewhere [7] .
Crossreactivity ELISA
Cross-reactivity was analysed in human sera that were reactive to both cTNC1 or cTNC5 and CEP-1, cVIM, cFIBβ or citrullinated homologous fibrinogen peptides. Sera were diluted 1:100, incubated with 1, 10 and 100 μg/ml of peptides for 2 hours, centrifuged at 10,000 g for 10 min and the supernatant added to peptide-coated plates for analysis by ELISA as described in Material and Methods.
Statistical Analysis and Software
Mann-Whitney U tests were used to calculate p values for differences between groups (GraphPad Prism). The 98% percentile of healthy control samples was used to define the cut-off for positive antibody levels. Chi-square tests were used to compare frequency distributions of categorical variables while t-tests and Wilcoxon rank-sum tests were used to compare all continuous variables. To determine the association of smoking, HLA-DRB1 SE (subtypes DRB1*01 (except DRB1*0103), DRB1*04 and DRB1*10), HLA-DRB1*13 and PTPN22 with different RA subsets, odds ratios (OR) with 95% Confidence Intervals (95% CI) were calculated using unconditional logistic regression models, with unexposed cases and controls as reference group. Analyses were adjusted for age, gender and residential area. All analyses were performed using SAS version 9.3. Heatmaps were generated using G-ProX and three-dimensional models were created using Pymol (Schrödinger, LLC). 
Supplementary Table 1. Sequences of FBG peptides used for ELISAs.

FBG peptides Sequence
rTNC1 (aa 2026-2040) CVFLRRKNG-R-ENFYQNWC cTNC1 CVFLRRKNG-cit-ENFYQNWC rTNC2 (aa 2042-2058) CAYAAGFGD-R-REEFWLGLC cTNC2 CAYAAGFGD-cit-REEFWLGLC rTNC3 (aa 2091-2106) CFSVGDAKT-R-YKLKVEGYC cTNC3 CFSVGDAKT-cit-YKLKVEGYC rTNC4 (aa 2141-2157) CKGAFWY-R-NCH-R-VNLMGRC cTNC4 CKGAFWY-cit-NCH-cit-VNLMGRC rTNC5 (aa 2183-2200) CEMKL-R-PSNF-R-NLEG-R-R-KRC cTNC5 CEMKL-cit-PSNF-cit-NLEG-cit-cit-KRC Supplementary
